Large Cap Biopharmaceuticals-Valuation Models 2016
July 04, 2016 at 02:41 AM EDT
The biotech sector has underperformed the market because of the severe correction in August/September of 2015 followed by another downdraft in January 2016 all the result of “bubble” valuations.
